Document Detail


Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.
MedLine Citation:
PMID:  17885577     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Clozapine is a unique atypical antipsychotic with superior efficacy in treatment-resistant schizophrenia. Plasma concentration of clozapine and its major metabolite N-desmethylclozapine (NDMC) as well as the ratio of NDMC to clozapine have been reported to be predictors of clozapine response. Here we evaluate these as well as other measures in an effort to find predictors of response to clozapine in our early-onset treatment-refractory population. METHOD: Fifty-four children and adolescents participated in double-blind (n = 22) or open-label (n = 32) clozapine trials. Clinical evaluations took place at baseline, week 6 on clozapine, and at 2- to 6-year follow-up. The data were analyzed in relation to demographics, age at onset, IQ, clozapine dose, and plasma concentrations of prolactin, clozapine, NDMC, and NDMC/clozapine ratio. Stepwise regression and correlation analyses were performed to find predictors of treatment response. RESULTS: Clinical improvement after 6 weeks of clozapine treatment, as measured by the percentage of improvement on the Brief Psychiatric Rating Scale and the Scale for the Assessment of Positive Symptoms, was strongly associated with the NDMC/clozapine ratio at the 6-week time point (Pearson correlation coefficient: r = 0.41; p < .01 for Brief Psychiatric Rating Scale and r = 0.43; p < .01 for Scale for the Assessment of Positive Symptoms). Although the rate of side effects was higher than that typically found in the adult population, it did not appear to be related to clozapine dose, clozapine or NDMC plasma concentrations, or NDMC/clozapine ratio. Outcome at long-term follow-up, as measured by Children's Global Assessment Scale, was associated with lesser illness severity at baseline and with greater improvement during the initial 6 weeks of clozapine treatment. CONCLUSIONS: The NDMC/clozapine ratio may be a valuable predictor of response to clozapine and may suggest new approaches to clozapine treatment.
Authors:
Alexandra L Sporn; Anoop Vermani; Deanna K Greenstein; Aaron J Bobb; Edgar P Spencer; Liv S Clasen; Julia W Tossell; Catherine C Stayer; Peter A Gochman; Marge C Lenane; Judith L Rapoport; Nitin Gogtay
Related Documents :
16709317 - Open-label olanzapine treatment in bipolar i disorder: clinical and work functional out...
10986547 - Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study...
17933497 - A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, ...
24302457 - The assessment of breathlessness in pulmonary arterial hypertension: reliability and va...
8324857 - High prevalence of mefloquine-resistant falciparum malaria in eastern thailand.
12140647 - Resting respiration in dysphagic patients following acute stroke.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural    
Journal Detail:
Title:  Journal of the American Academy of Child and Adolescent Psychiatry     Volume:  46     ISSN:  0890-8567     ISO Abbreviation:  J Am Acad Child Adolesc Psychiatry     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-09-21     Completed Date:  2007-11-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8704565     Medline TA:  J Am Acad Child Adolesc Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1349-56     Citation Subset:  IM    
Affiliation:
Child Psychiatry Branch, NIMH, Bethesda, MD, USA. als2168@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Age of Onset
Antipsychotic Agents / adverse effects,  therapeutic use*
Brief Psychiatric Rating Scale
Child
Clozapine / adverse effects,  therapeutic use*
Double-Blind Method
Drug Therapy / standards*
Female
Humans
Male
Schizophrenia, Childhood / diagnosis,  drug therapy*,  epidemiology*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Who gets care? Mental health service use following a school-based suicide prevention program.
Next Document:  Efficiency of the prefrontal cortex during working memory in attention-deficit/hyperactivity disorde...